SHR-1819 is named as an intervention in 4 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Guangdong Hengrui Pharmaceutical Co., Ltd. The most-studied condition is Moderate-to-severe Atopic Dermatitis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
NCT07309055 · ClinicalTrials.gov ↗ · Adolescents With Moderate-to-severe Atopic Dermatitis
|
Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | China |
|
A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
NCT07688772 · ClinicalTrials.gov ↗ · Seasonal Allergic Rhinitis
|
Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | China |
|
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
NCT06554509 · ClinicalTrials.gov ↗ · Prurigo Nodularis
|
Phase 2/3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | China |
|
A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis
NCT07321951 · ClinicalTrials.gov ↗ · Moderate-to-severe Atopic Dermatitis
|
Phase 2 | Active, closed | Guangdong Hengrui Pharmaceutical Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Guangdong Hengrui Pharmaceutical Co., Ltd | 4 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 3 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name SHR-1819 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 4 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Guangdong Hengrui Pharmaceutical Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SHR-1819 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SHR-1819 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SHR-1819 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.